Search Results
Your search for The matches 35406 pages
Showing 6351 - 6400Novel Photon-Counting CT May Improve Myeloma Bone Disease Detection
New computed tomography (CT) technology paired with artificial intelligence (AI)-based noise reduction may offer superior detection of bone disease associated with multiple myeloma at lower radiation doses than conventional CT, according to a recent study published by Baffour et al in Radiology....
Recurrence-Free Survival as Surrogate for Overall Survival in Patients Undergoing Resection of Colorectal Liver Metastases
In a single-center retrospective study and a separate meta-analysis reported in The Lancet Oncology, Ecker et al found low correlations between recurrence-free survival and overall survival among patients undergoing resection of colorectal cancer liver metastases. As stated by the investigators,...
Compliance of NCI-Designated Cancer Centers With January 2021 CMS Price Transparency Requirements
In a study reported in JAMA Surgery, Childers et al found that only one-third of hospitals with National Cancer Institute (NCI)-designated cancer center status were fully compliant with Centers for Medicare & Medicaid Services (CMS) price transparency requirements instituted in January 2021....
Reporting of Hispanic Ethnicity and Race in Breast Cancer Studies: National Cancer Database Analysis
In a National Cancer Database (NCDB) analysis reported in a research letter in JAMA Oncology, Bazan et al found that Hispanic ethnicity was reported in patient demographics or results in less than half of studies in breast cancer, with a smaller proportion categorizing race and ethnicity into...
National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
Approximately 6% of patients with stage I to III lung cancer develop a second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer.1 Analysis of data...
Highlights From the ESMO Congress 2022
The ESMO Congress 2022 took place in Paris from September 9 to 13. In this episode, we highlight key research presented at the meeting. We’ll first hear from the presenting author of Abstract LBA1 on the effect of air pollutants on the risk of non–small cell lung cancer. Then, we’ll hear from a...
New Research From Cohort K of the EV-103 Trial of Enfortumab Vedotin for Patients With Urothelial Cancer
Researchers from Memorial Sloan Kettering (MSK) Cancer Center shared data on a treatment option for patients with bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA73). Jonathan E. Rosenberg, MD, medical oncologist and Chief of the Genitourinary Oncology...
Costs of Cancer Treatment for Younger, Privately Insured Patients
A new, large study led by researchers at the American Cancer Society (ACS) and The University of Texas MD Anderson Cancer Center showed the rising costs of cancer treatment led to increases in total costs of care, and when compounded with greater cost-sharing, increased out-of-pocket costs for...
Cost-Effectiveness of Chemotherapy Sequences in Metastatic Breast Cancer According to Prior Therapy Exposure
In a modeling study reported in the Journal of Clinical Oncology, Stephanie B. Wheeler, PhD, MPH, and colleagues identified the most cost-effective sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative metastatic breast cancer according to prior ...
Use of Trimodality Therapy in Stage II/III Rectal Cancer in the United States: 10-Year Period
In a retrospective cohort study reported in JAMA Oncology, Hagen F. Kennecke, MD, and colleagues found that among U.S. patients with clinical stage II/III rectal cancer diagnosed between 2006 and 2016 who received trimodality therapy, use of postoperative chemoradiation therapy (CRT) decreased and...
Rezvilutamide vs Bicalutamide Combined With ADT in High-Volume Metastatic Hormone-Sensitive Prostate Cancer
As reported in The Lancet Oncology by Gu et al, interim analyses of the phase III CHART trial have shown improved radiographic progression-free survival and overall survival with the novel androgen receptor inhibitor rezvilutamide vs bicalutamide when both were combined with androgen-deprivation...
Tony S.K. Mok, MD, on NSCLC: Review of Recent Data From the SUNRISE and ORIENT-31 Trials
Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses two late-breaking abstracts presented at ESMO 2022: the phase II SUNRISE study, which compared sintilimab plus anlotinib vs platinum-based chemotherapy as first-line therapy in patients with metastatic non–small cell lung cancer...
Matteo Lambertini, MD, PhD, on Oncofertility Care for Young Women With Breast Cancer
Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, talks about why oncofertility counseling should now be considered mandatory in the care of young women with breast cancer. Among the treatments he recommends offering are oocyte/embryo cryopreservation (or ...
Georgina V. Long, MD, PhD, on Melanoma: Findings on Circulating Tumor DNA, Disease Recurrence, and Immunotherapy
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and translational baseline factors, and their association with disease recurrence in patients with stage...
Sequencing of Ipilimumab/Nivolumab With Encorafenib/Binimetinib in BRAF-Mutant Metastatic Melanoma
In a phase II trial (SECOMBIT) reported in the Journal of Clinical Oncology, Paolo A. Ascierto, MD, and colleagues found that sequential immunotherapy and targeted therapy with ipilimumab/nivolumab followed at disease progression by encorafenib/binimetinib was associated with good survival...
Expert Point of View: Jacek Jassem, MD
Abstract discussant, Jacek Jassem, MD, of the Medical University of Gdansk, in Poland, underscored smoking as the most important cause of lung cancer, noting that between 85% and 90% of patients with lung cancer are current or former smokers. “Lung cancer screening, which has recently become...
High-Intensity Intervention Helps One-Third of Participants in Lung Cancer Screening Program Quit Smoking
Despite significant advancements in cancer therapy, a primary means to avoid lung cancer is prevention, and smoking cessation is the most basic intervention. Unfortunately, for long-term smokers, that intervention can sometimes be the most challenging. According to data presented during the...
Trends in Incidence of Cutaneous T-Cell Lymphoma in the United States
In a study reported in a research letter in JAMA Oncology, Cai et al found that the incidence of cutaneous T-cell lymphoma increased in the United States between 2000 and 2018. The study involved data from 18 Surveillance, Epidemiology, and End Results (SEER) Program registries for 2000 to 2018. A...
Association of Neurofilament Light Chain Levels With ICANS Risk After CAR T-Cell Therapy
In a retrospective study reported in JAMA Oncology, Butt et al found significantly higher pretreatment neurofilament light chain levels in patients who did vs did not develop immune effector cell–associated neurotoxicity syndrome (ICANS) after CD19 chimeric antigen receptor (CAR) T-cell therapy....
Lung Cancer Screening Increases Percentage of Stage I Cases Detected, While Reducing Percentage of Stage IV Cases Detected
Implementing lung cancer screening at four diverse health-care systems resulted in an 8.4% increase in the number of stage I lung cancers detected and a 6.6% decrease in the detection of stage IV disease, according to research published by Vachani et al in the Journal of Thoracic Oncology. The...
Study Explores Link Between Use of Antipsychotic Agents and Increased Breast Cancer Risk
A research team from the Centre for Safe Medication Practice and Research (CSMPR) in the Department of Pharmacology and Pharmacy at the University of Hong Kong (HKUMed) conducted a systematic review and meta-analysis of observational studies with over 2 million individuals and estimated a moderate...
Neil D. Gross, MD, on Cutaneous Squamous Cell Carcinoma: Recent Findings on Cemiplimab
Neil D. Gross, MD, of The University of Texas MD Anderson Cancer Center, discusses data from a phase II study, which showed that neoadjuvant cemiplimab-rwlc in patients with stage II–IV (M0) resectable cutaneous squamous cell carcinoma is active and may enable function-preserving surgery in some...
Patient-Reported Outcomes With the Addition of Olaparib to Abiraterone in Castration-Resistant Prostate Cancer
As reported in The Lancet Oncology by Fred Saad, MD, FRCS, and colleagues, an analysis of a phase II trial found no significant differences in health-related quality of life or pain measures with the addition of olaparib to abiraterone in patients with metastatic castration-resistant prostate...
Outcomes of Lung Cancer Screening in Individuals With or Without Lung-Related Comorbidities
In a prospective cohort study reported in JAMA Network Open, Metwally et al found no significant differences in positive examination, cancer detection, or false-positive rates among individuals with vs without self-reported lung-related comorbidities undergoing low-dose computed tomography lung...
5-Year Outcomes With Adjuvant mFOLFIRINOX vs Gemcitabine in Pancreatic Cancer
As reported in JAMA Oncology by Thierry Conroy, MD, and colleagues, 5-year analysis of the phase III PRODIGE 24/Canadian Cancer Trials Group PA6 trial has shown a significant benefit in overall survival and other outcomes with adjuvant mFOLFIRINOX (modified oxaliplatin, irinotecan, leucovorin, and...
Acquired EGFR Inhibitor Resistance Alterations Identified in ctDNA Analysis in Patients With Refractory Metastatic Colorectal Cancer
In a study reported in the Journal of Clinical Oncology by Topham et al, circulating tumor DNA (ctDNA) analysis indicated significantly increased frequencies of multiple potential EGFR inhibitor resistance alterations among patients with refractory metastatic colorectal cancer with vs without prior ...
Updated Overall Survival Findings With Adjuvant Erlotinib vs Vinorelbine/Cisplatin in EGFR-Mutant Stage IIIA NSCLC
As reported in the Journal of Clinical Oncology by Yue et al, an updated analysis of the Chinese phase II EVAN study indicated a sizable overall survival advantage with adjuvant erlotinib vs vinorelbine/cisplatin in patients with R0 resected stage IIIA EGFR-mutant non–small cell lung cancer...
Gérard Zalcman, MD, PhD, on Non–Small Cell Lung Cancer: Phase III Trial Findings on Nivolumab and Ipilimumab
Gérard Zalcman, MD, PhD, of France’s Bichat-Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, discusses phase III results from the IFCT-1701 trial, which explored the questions of whether to administer nivolumab plus ipilimumab for 6 months or whether to prolong the treatment in...
Jean-Pascal Machiels, MD, PhD, on Head and Neck Cancer: Recent Data on Pembrolizumab and Chemoradiation Therapy
Jean-Pascal Machiels, MD, PhD, of Belgium’s Cliniques universitaires Saint-Luc (UCLouvain), discusses the primary results of the phase III KEYNOTE-412 study of pembrolizumab plus chemoradiation therapy (CRT) vs placebo plus CRT for patients with locally advanced head and neck squamous cell...
Neal D. Shore, MD, on Prostate Cancer: Biomarker Analysis, Enzalutamide, and Active Surveillance
Neal D. Shore, MD, of Carolina Urologic Research Center/Genesis Care, discusses new data from the ENACT trial, which showed that patients with prostate cancer and the RNA biomarkers PAM50 and AR-A were likely to have better outcomes with enzalutamide treatment. The results suggest that such RNA...
Adjuvant Atezolizumab Does Not Improve Disease-Free Survival in Patients With Renal Cell Carcinoma
Adjuvant therapy with the anti–PD-L1 therapy atezolizumab failed to improve disease-free survival compared to placebo in patients with renal cell carcinoma (RCC) at high risk of recurrence after resection, according to results of the phase III IMmotion010 trial presented by Axel Bex, MD, PhD, at...
Updated Results From the ADAURA Trial of Adjuvant Osimertinib in EGFR-Mutated NSCLC
Newly released results from the phase III ADAURA trial revealed that osimertinib yielded a 5.5-year median disease-free survival in the postsurgical treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC), and nearly three in four patients treated with adjuvant osimertinib were...
Dual Checkpoint Inhibitor Blockade as First-Line or Salvage Therapy for Patients With Advanced Merkel Cell Carcinoma
Merkel cell carcinoma has a high rate of metastasis and poor patient outcomes. The current standard of care for patients with recurrent, unresectable, or metastatic disease is immune checkpoint inhibitor monotherapy targeting PD-1 and PD-L1, but only about half of patients respond to this therapy....
Early Research Identifies Effective Combination Immunotherapy for Subgroup of Patients With Metastatic Colorectal Cancer
A physician-scientist at City of Hope has identified a novel combination immunotherapy regimen—a triplet therapy consisting of regorafenib, ipilimumab, and nivolumab—that demonstrated significant response in patients with chemotherapy-resistant, microsatellite-stable metastatic colorectal cancer....
ASCO Applauds President Biden’s Leadership in Relaunching the Cancer Moonshot
On September 12, Lori J. Pierce, MD, FASTRO, FASCO, Board Chair of the Association for Clinical Oncology (ASCO), made the following statement: “President John F. Kennedy’s historic speech that inspired our nation and an entire generation of Americans to achieve manned space exploration underscored ...
Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Recent Phase III Data on Cabozantinib, Nivolumab, and Ipilimumab From the COSMIC-313 Trial
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss phase III findings showing that cabozantinib in combination with nivolumab and ipilimumab reduced the risk of disease progression or death compared with the...
Axel Bex, MD, PhD, on Renal Cell Carcinoma: Phase III Results With Atezolizumab as Adjuvant Therapy
Axel Bex, MD, PhD, of the Netherlands Cancer Institute, discusses phase III findings from the IMmotion010 study, which evaluated the efficacy and safety of atezolizumab vs placebo in patients with renal cell cancer who are at high risk of disease recurrence following nephrectomy (Abstract LBA66).
Martin Reck, MD, PhD, on NSCLC: New Findings on Cemiplimab, Nivolumab, and Ipilimumab
Martin Reck, MD, PhD, of Germany’s Lung Clinic Grosshansdorf, details two trials that included patients with advanced non–small cell lung cancer: 3-year survival outcomes in the EMPOWER-Lung 1 study of continued cemiplimab-rwlc beyond disease progression with the addition of chemotherapy, and phase ...
Richard S. Finn, MD, on Hepatocellular Carcinoma: Recent Data on Lenvatinib Plus Pembrolizumab
Richard S. Finn, MD, of the Geffen School of Medicine at the University of California, Los Angeles, discusses primary phase III results from the LEAP-002 study of pembrolizumab, an anti–PD-1 therapy, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor, vs lenvatinib...
Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Review of Two Key Abstracts on Belzutifan Plus Cabozantinib and Pembrolizumab Plus Lenvatinib
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss results from two important trials presented at ESMO 2022: Cohort 1 of the LITESPARK-003 study of belzutifan plus cabozantinib as first-line treatment of...
Charles Swanton, PhD, on Non–Small Cell Lung Cancer Induced by Air Pollution
Charles Swanton, PhD, of The Francis Crick Institute, discusses a newly discovered mechanism of action for air pollution–induced non–small cell lung cancer in which particles linked to climate change appear to promote cancerous changes. The finding might pave the way for new potential approaches to ...
FRESCO-2: Fruquintinib for Patients With Refractory Metastatic Colorectal Cancer
Researchers reported study results showing that fruquintinib, a small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR), significantly improved overall survival and progression-free survival in patients with refractory metastatic colorectal cancer. Findings...
Neoadjuvant Cemiplimab in Patients With Stage II to IV Cutaneous Squamous Cell Carcinoma
In an international, multicenter phase II clinical trial, 63.3% of patients with stage II to IV cutaneous squamous cell carcinoma saw their tumors nearly or completely eradicated when treated with the anti–PD-1 agent cemiplimab-rwlc before surgery. The results were presented by Gross et al at the...
Updated Results From the KRYSTAL-1 Study of Adagrasib in Advanced KRAS G12C–Mutated Colorectal Cancer
Updated results from KRYSTAL-1, a multicohort phase I/II study, evaluating adagrasib—an investigational, highly selective, and potent oral small-molecule inhibitor of KRAS G12C—with or without cetuximab in patients with advanced colorectal cancer harboring a KRAS G12C mutation were presented by...
Research Explores Multicancer Early Detection Blood Testing
Physicians, care providers, and payers may be preparing for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment. New data supporting the accuracy of multicancer early detection blood testing, presented by Deb Schrag, MD, FASCO, MPH, at the...
SWOG S1801: Neoadjuvant and Adjuvant Pembrolizumab for Patients With Stage IIIB to IV Melanoma
Patients with high-risk melanoma who received the anti–PD-1 therapy pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery. These results from a study by the SWOG...
Marinde J.G. Bond, PhD Candidate, on Colorectal Liver Metastases: FOLFOX/FOLFIRI, Bevacizumab, and Panitumumab
Marinde J.G. Bond, PhD Candidate, of the University Medical Center, Utrecht, discusses phase III findings from the CAIRO5 study of the Dutch Colorectal Cancer Group, the first such trial in defined subgroups of patients with initially unresectable colorectal cancer liver metastases and left-sided...
Sapna P. Patel, MD, on Melanoma: New Data on Pembrolizumab, Adjuvant vs Neoadjuvant Plus Adjuvant
Sapna P. Patel, MD, of The University of Texas MD Anderson Cancer Center, discusses the latest findings from the SWOG S1801 trial, which showed that using single-agent pembrolizumab as neoadjuvant therapy improved event-free survival compared to adjuvant therapy in high-risk resectable stage III–IV ...
Antonio Marra, MD, on Metastatic Breast Cancer: Patterns of Genomic Instability and Their Effect on Treatment
Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses a mutational signature analysis that reveals patterns of genomic instability linked to resistance to endocrine therapy with or without CDK4/6 inhibition in patients with estrogen receptor–positive/HER2-negative metastatic...
Ana Oaknin, MD, PhD, on Cervical Cancer: Safety and Efficacy Results With Nivolumab and Ipilimumab
Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses findings from the CheckMate 358 trial, which showed that chemotherapy-free immunotherapy with nivolumab alone or in combination with ipilimumab may provide durable tumor regression with manageable toxicity in patients...
